What is metoclopramide used for?

Indications and Usage, quoted from the label by ScieGen Pharmaceuticals, Inc. (ANDA072215). Cross-references to other label sections are left out.

Metoclopramide tablets are indicated for the:

• Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy.
• Relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

Limitations of Use:

• Metoclopramide tablets have not been shown to be safe and effective for the treatment of symptomatic, documented gastroesophageal reflux for longer than 12 weeks.
• Metoclopramide tablets are not recommended for use in pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates.

Source: DailyMed label, set id b16ad17c-eeea-407e-91e4-36506e9aa698, version 5, effective April 30, 2026. NDC 50228-232, one of 37 listings for this product.

Indications and Usage, quoted from the label by Teva Parenteral Medicines, Inc. (ANDA073135). Cross-references to other label sections are left out.

Diabetic Gastroparesis

Metoclopramide injection is indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis is in adults.

The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy

Metoclopramide injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy in adults.

The Prevention of Postoperative Nausea and Vomiting

Metoclopramide injection is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable in adults.

Small Bowel Intubation

Metoclopramide injection is indicated to facilitate small bowel intubation in adult and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers.

Radiological Examination

Metoclopramide injection is indicated to stimulate gastric emptying and intestinal transit of barium where delayed emptying interferes with radiological examination of the stomach and/or small intestine in adults.

Source: DailyMed label, set id 5645a752-8868-4b51-8b59-48bb4276d763, version 8, effective April 15, 2026. NDC 0703-4502, one of 17 listings for this product.

Indications and Usage, quoted from the label by ATLANTIC BIOLOGICALS CORP. (ANDA072744). Cross-references to other label sections are left out.

The use of Metoclopramide Oral Solution is recommended for adults only. Therapy should not exceed 12 weeks in duration.

Symptomatic Gastroesophageal Reflux

Metoclopramide Oral Solution USP is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy.

The principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically.

Diabetic Gastroparesis (diabetic gastric stasis)

Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three-week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more.

Source: DailyMed label, set id 3cd4b274-6176-4e5b-9765-4f50763bd58f, version 9, effective July 10, 2026. NDC 17856-0576, one of 14 listings for this product.